Protara Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
Related news for (TARA)
- Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer
- Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
- Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
- Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025
- Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer